Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
55.96
-0.23 (-0.41%)
Nov 13, 2024, 4:00 PM EST - Market closed

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $6.60 billion. The enterprise value is $6.41 billion.

Market Cap 6.60B
Enterprise Value 6.41B

Important Dates

The last earnings date was Wednesday, November 6, 2024, after market close.

Earnings Date Nov 6, 2024
Ex-Dividend Date n/a

Share Statistics

Cytokinetics has 118.01 million shares outstanding. The number of shares has increased by 12.36% in one year.

Current Share Class 118.01M
Shares Outstanding 118.01M
Shares Change (YoY) +12.36%
Shares Change (QoQ) +7.73%
Owned by Insiders (%) 0.48%
Owned by Institutions (%) 117.01%
Float 117.42M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1,991.04
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 9.28

Current Ratio 9.28
Quick Ratio 9.22
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -6.48

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -30.13%
Return on Capital (ROIC) -60.40%
Revenue Per Employee $7,610
Profits Per Employee -$1.36M
Employee Count 423
Asset Turnover 0.00
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +75.45% in the last 52 weeks. The beta is 0.78, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y) 0.78
52-Week Price Change +75.45%
50-Day Moving Average 54.20
200-Day Moving Average 60.40
Relative Strength Index (RSI) 59.13
Average Volume (20 Days) 1,094,463

Short Selling Information

The latest short interest is 15.69 million, so 13.29% of the outstanding shares have been sold short.

Short Interest 15.69M
Short Previous Month 15.54M
Short % of Shares Out 13.29%
Short % of Float 13.36%
Short Ratio (days to cover) 12.11

Income Statement

In the last 12 months, Cytokinetics had revenue of $3.22 million and -$576.40 million in losses. Loss per share was -$5.38.

Revenue 3.22M
Gross Profit -327.54M
Operating Income -524.63M
Pretax Income -545.28M
Net Income -576.40M
EBITDA -511.14M
EBIT -524.63M
Loss Per Share -$5.38
Full Income Statement

Balance Sheet

The company has $1.01 billion in cash and $789.63 million in debt, giving a net cash position of $222.07 million or $1.88 per share.

Cash & Cash Equivalents 1.01B
Total Debt 789.63M
Net Cash 222.07M
Net Cash Per Share $1.88
Equity (Book Value) -13.91M
Book Value Per Share -0.12
Working Capital 908.79M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$404.36 million and capital expenditures -$2.69 million, giving a free cash flow of -$407.05 million.

Operating Cash Flow -404.36M
Capital Expenditures -2.69M
Free Cash Flow -407.05M
FCF Per Share -$3.45
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -16,297.79%
Pretax Margin -17,906.24%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin -12,803.89%

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -12.36%
Shareholder Yield -12.36%
Earnings Yield -8.67%
FCF Yield -6.13%
Dividend Details

Analyst Forecast

The average price target for Cytokinetics is $83.67, which is 49.52% higher than the current price. The consensus rating is "Buy".

Price Target $83.67
Price Target Difference 49.52%
Analyst Consensus Buy
Analyst Count 16
Revenue Growth Forecast (5Y) 193.39%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date Jun 25, 2013
Split Type Reverse
Split Ratio 0.1666666:1

Scores

Cytokinetics has an Altman Z-Score of -0.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.42
Piotroski F-Score 2